iHuman
7 hedge funds and large institutions have $8.02M invested in iHuman in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
8% more capital invested
Capital invested by funds: $7.46M → $8.02M (+$568K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.11% less ownership
Funds ownership: 2.88% → 2.77% (-0.11%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$7.76K |
| 2 |
BlackRock
New York
|
+$461 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$417K |
| 2 |
Millennium Management
New York
|
-$24K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.04K |
| 4 |
State Street
Boston,
Massachusetts
|
-$348 |
IH Hedge Fund Activity: Q2 2022 in Review
7 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in iHuman (IH) for Q2 2022, worth a combined $8.02M — up 7.6% from $7.46M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IH positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $7.76K. The largest seller was Morgan Stanley, cutting an estimated $417K.
- 7 institutional investors held iHuman (IH) as of Q2 2022, up from 6 in Q1 2022.
- Funds reported $8.02M of iHuman stock for Q2 2022, up 7.6% quarter-over-quarter.
- 2 funds opened new iHuman positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest iHuman buyer in Q2 2022 was UBS Group, an estimated $7.76K added.
- The largest iHuman seller in Q2 2022 was Morgan Stanley, an estimated $417K sold.
Based on aggregated 13F filings for Q2 2022.